Joincare Pharmaceutical Group Industry Co.,Ltd.

SHSE:600380 주식 보고서

시가총액: CN¥21.9b

Joincare Pharmaceutical Group IndustryLtd 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Xiong Yu

최고 경영자

CN¥3.6m

총 보상

CEO 급여 비율72.2%
CEO 임기no data
CEO 소유권n/a
경영진 평균 재임 기간데이터 없음
이사회 평균 재임 기간데이터 없음

최근 관리 업데이트

Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

May 31
Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

Recent updates

Is Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) A Risky Investment?

Nov 17
Is Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) A Risky Investment?

Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market

Aug 13
Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market

We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease

Jun 23
We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease

Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

May 31
Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings

Apr 09
Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings

Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel

Mar 04
Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel

CEO 보상 분석

Xiong Yu 의 보수는 Joincare Pharmaceutical Group IndustryLtd 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

CN¥1b

Jun 30 2024n/an/a

CN¥1b

Mar 31 2024n/an/a

CN¥1b

Dec 31 2023CN¥4mCN¥3m

CN¥1b

Sep 30 2023n/an/a

CN¥1b

Jun 30 2023n/an/a

CN¥2b

Mar 31 2023n/an/a

CN¥2b

Dec 31 2022CN¥4mCN¥3m

CN¥2b

Sep 30 2022n/an/a

CN¥1b

Jun 30 2022n/an/a

CN¥1b

Mar 31 2022n/an/a

CN¥1b

Dec 31 2021CN¥3mCN¥2m

CN¥1b

보상 대 시장: Xiong 의 총 보상 ($USD 496.74K )은 CN 시장( $USD 209.90K ).

보상과 수익: Xiong 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Xiong Yu (63 yo)

no data

테뉴어

CN¥3,600,000

보상

Mr. Xiong Yu serves as Sichuan Biokin Pharmaceutical Co.,Ltd. since September 17, 2019. He served as Non-Executive Director of Livzon Pharmaceutical Group Inc. since June 30, 2020 until October 14, 2024.H...